Walther Lisa, Gantner Andreas, Heinz Andreas, Majić Tomislav
Department of Psychiatry and Psychotherapy Charité-Universitätsmedizin Berlin, Campus Mitte, Therapieladen e. V., Berlin, Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Charité Campus Mitte at St. Hedwig Hospital, Charité Campus Mitte.
Dtsch Arztebl Int. 2016 Sep 30;113(39):653-659. doi: 10.3238/arztebl.2016.0653.
Now that the consumption of natural and synthetic cannabinoids is becoming more widespread, the specific treatment of cannabis-related disturbances is an increasingly important matter. There are many therapeutic options, and it is not always clear which ones are evidence-based and appropriate for use in a given clinical situation.
This review is based on reports of pertinent randomized and controlled trials (RCTs) that were retrieved by a selective search in the PubMed and Cochrane databases.
Cognitive behavior therapy (CBT) combined with other techniques has been found to have a moderate to large effect (Cohen's d = 0.53-0.9) on the amount of cannabis consumed as well as on the level of psychosocial functioning or the dependence syndrome. Systemic multidimensional family therapy (MDFT) has been found beneficial for younger adolescents who consume large amounts of cannabis and have psychiatric comorbidities. Short-term interventions with motivational talk therapy have been found effective for patients with or without an initial desire to achieve cannabis abstinence. All of these psychotherapeutic interventions are effective at evidence level Ia. The administration of gabapentin had a weak effect (d = 0.26) on the quantity consumed and on abstinence (evidence level Ib). Withdrawal symptoms can be alleviated with cannabinoid-receptor antagonists (d = 0.223 and 0.481) (evidence level Ib). On the other hand, there is evidence that serotonergic antidepressants can worsen withdrawal manifestations and increase the likelihood of relapse.
Psychotherapeutic techniques remain the foundation of treatment for cannabis dependence. No drug has yet been approved for the treatment of cannabis dependence because of the lack of scientific evidence. The rates of abstinence that are currently achieved, even with psychotherapy, are still only moderate. Further clinical studies are needed for the evaluation of combinations of various treatments that can meet the needs of individual patients.
鉴于天然和合成大麻素的使用日益广泛,大麻相关障碍的特异性治疗成为一个日益重要的问题。有许多治疗选择,但并不总是清楚哪些是基于证据且适用于特定临床情况的。
本综述基于通过在PubMed和Cochrane数据库中进行选择性检索获得的相关随机对照试验(RCT)报告。
认知行为疗法(CBT)与其他技术相结合已被发现对大麻使用量以及心理社会功能水平或依赖综合征有中度至较大影响(科恩d值 = 0.53 - 0.9)。系统性多维家庭治疗(MDFT)已被发现对大量使用大麻且患有精神疾病共病的青少年有益。动机谈话疗法的短期干预已被发现对有或没有初始戒除大麻意愿的患者有效。所有这些心理治疗干预在证据水平Ia上都是有效的。加巴喷丁的给药对使用量和戒除有微弱影响(d = 0.26)(证据水平Ib)。大麻素受体拮抗剂可缓解戒断症状(d = 0.223和0.481)(证据水平Ib)。另一方面,有证据表明血清素能抗抑郁药会使戒断表现恶化并增加复发的可能性。
心理治疗技术仍然是大麻依赖治疗的基础。由于缺乏科学证据,尚无药物被批准用于治疗大麻依赖。即使采用心理治疗目前实现的戒除率仍然仅为中等。需要进一步的临床研究来评估各种治疗组合以满足个体患者的需求。